Literature DB >> 31999866

A same day 'test and treat' model for chronic HCV and HBV infection: Results from two community-based pilot studies in Egypt.

Gamal Shiha1,2, Reham Soliman1,3, Abdalhamed Serwah4, Nabiel N H Mikhail1,5, Tarik Asselah6, Philippa Easterbrook7.   

Abstract

Prompt access to confirmatory viral load testing and staging of liver disease are key barriers in uptake of treatment for chronic hepatitis B and C infection. Our objective was to establish the feasibility of a same day 'test and treat' model in two distinct community-based settings in Egypt through use of key point-of-care (POC) portable tools for HCV and HBV viral load assessment and staging of liver disease followed by treatment initiation. Community sites were a village in northern Egypt (site 1) and a government office in Cairo (site 2). The following model was adopted: community awareness raising in the week before project initiation; site assessment to ensure optimal placement and calibration of equipment and clinical care set-up; transfer of key portable laboratory instruments to the sites (four cartridge GeneXpert, FibroScan and abdominal ultrasound); screening using rapid diagnostic tests for HCV-Ab and HBsAg, with immediate venous or finger-stick blood sampling for HCV-RNA and HBV-DNA assay, FibroScan staging of liver disease and ultrasound screening for liver cancer. At site 1, 475 individuals were screened over a single day, 125 were positive for HCV-Ab and 4 for HBsAg, 43 of 56 new HCV diagnoses were HCV RNA positive, and 3 of 4 HBsAg positive were HBV DNA positive, 40 initiated HCV treatment, and one HBV treatment . At site 2, 3188 individuals were screened over 3 days, 157 were positive for HCV-Ab, and 27 for HBsAg; 38 of 76 new HCV diagnoses were HCV RNA positive, and 15 of 18 HBsAg positive were HBV-DNA positive. Across both sites, 78 patients were counselled and initiated on treatment for HCV and 12 for HBV within 3 and 4 hours, respectively, of initial positive rapid diagnostic test result. We have shown the feasibility of a same day 'test and treat' model for chronic HCV and HBV infection in two community-based settings in Egypt that achieved high levels of linkage to care and initial treatment.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV elimination; hepatitis; linkage to care; test and treat

Mesh:

Substances:

Year:  2020        PMID: 31999866     DOI: 10.1111/jvh.13268

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

Review 1.  Regional progress towards hepatitis C elimination in the Western Pacific Region, 2015-2020.

Authors:  Po-Lin Chan; Linh-Vi Le; Naoko Ishikawa; Philippa Easterbrook
Journal:  Glob Health Med       Date:  2021-10-31

2.  A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.

Authors:  Sunil S Solomon; Sandra Wagner-Cardoso; Laura Smeaton; Leonard A Sowah; Chanelle Wimbish; Gregory Robbins; Irena Brates; Christine Scello; Annie Son; Anchalee Avihingsanon; Benjamin Linas; Donald Anthony; Estevão Portela Nunes; Dimas A Kliemann; Khuanchai Supparatpinyo; Cissy Kityo; Pablo Tebas; Jaclyn Ann Bennet; Jorge Santana-Bagur; Constance A Benson; Marije Van Schalkwyk; Nelson Cheinquer; Susanna Naggie; David Wyles; Mark Sulkowski
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-01-10

3.  Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study.

Authors:  Daan W Von den Hoff; Floor A C Berden; Femke Atsma; Arnt F A Schellekens; Joost P H Drenth
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

4.  Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study.

Authors:  Innocent Kamali; Fabienne Shumbusho; Dale A Barnhart; Françoise Nyirahabihirwe; Jean de la Paix Gakuru; Wellars Dusingizimana; Esdras Nizeyumuremyi; Placide Habinshuti; Stephen Walker; Jean Damascene Makuza; Janvier Serumondo; Gallican Nshogoza Rwibasira; Jean d'Amour Ndahimana
Journal:  BMC Infect Dis       Date:  2022-03-21       Impact factor: 3.090

5.  Feasibility of decentralised, task-shifted hepatitis C testing and treatment services in urban Myanmar: implications for scale-up.

Authors:  Bridget Louise Draper; Win Lei Yee; Sonjelle Shilton; Anna Bowring; Hla Htay; Nwe Nwe; Jessica Markby; Khin Pyone Kyi; Philippa Easterbrook; Win Naing; Thin Mar Win; Khin Sanda Aung; Jessica Howell; Alisa Pedrana; Margaret Hellard
Journal:  BMJ Open       Date:  2022-05-03       Impact factor: 3.006

6.  Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs.

Authors:  Håvard Midgard; Ronny Bjørnestad; Maren Egeland; Eivin Dahl; Ane-Kristine Finbråten; Knut B Kielland; Martin Blindheim; Olav Dalgard
Journal:  Liver Int       Date:  2022-04-12       Impact factor: 8.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.